Skip to main content
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. — Investor Relations & Filings

Ticker · MCRB ISIN · US81750R2013 LEI · 549300GMXBE5NUWISF13 US Manufacturing
Open in API
Filings indexed 668 across all filing types
Latest filing 2022-08-03 Earnings Release
Country US United States of America
Listing US MCRB

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Seres Therapeutics, Inc. is a commercial-stage biotechnology company developing microbiome-based therapeutics. The company's platform creates a novel class of biological drugs, known as live biotherapeutics, which consist of rationally selected consortia of live bacteria. These therapies are designed to modulate the functional properties of the gastrointestinal microbiome to treat and prevent diseases. Seres' development programs target medically vulnerable patient populations, with a focus on preventing bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as treating gastrointestinal-related immune diseases.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 3, 2022, by Seres Therapeutics, Inc. It announces the company's financial results for the quarter ended June 30, 2022, and provides operational updates. The text explicitly states that the announcement is furnished as an exhibit (Exhibit 99.1) and is a press release. The document does not contain the full financial statements or detailed financial analysis itself but rather a summary announcement of quarterly results. According to the filing definitions, an initial announcement of quarterly financial results (key highlights only) corresponds to an Earnings Release (ER). The document length is 3725 characters, which is relatively short and consistent with a press release announcement rather than a full interim report. Therefore, the correct classification is Earnings Release (ER).
2022-08-03 English
SC 13D/A
Major Shareholding Notification
2022-07-22 English
SC 13D/A
Major Shareholding Notification
2022-07-07 English
FORM 3 SUBMISSION
Director's Dealing
2022-07-07 English
FORM 4 SUBMISSION
Director's Dealing
2022-07-07 English
FORM 4 SUBMISSION
Director's Dealing
2022-07-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.